BridgeBio Pharma BBIO Research and Development Services — Deferred revenue, current portion
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
As of March 31, 2026 and December 31, 2025, there were $10.2 million and $5.0 million, respectively, of outstanding receivables relating to the Bayer License Agreement on our condensed consolidated balance sheets. During the three months ended March 31, 2026 and 2025, we recognized license and services revenue and royalty revenue of $10.3 million and $76.1 million, respectively, under the Bayer License Agreement. Our condensed consolidated balance sheet as of March 31, 2026 includes a deferred revenue balance of $2.7 million ($0.8 million presented as “Deferred revenue, current portion” and $1.9 million as “Deferred revenue, net of current portion”) related to our research and development services obligations. Our condensed consolidated balance sheet as of December 31, 2025, includes a deferred revenue balance of $2.9 million ($0.8 million presented as “Deferred revenue, current portion” and $2.1 million as “Deferred revenue, net of current portion”) related to our research and development services obligations.
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's research and development services — deferred revenue, current portion?
- BridgeBio Pharma (BBIO) reported research and development services — deferred revenue, current portion of $800K in Q1 2026.
- What does research and development services — deferred revenue, current portion mean?
- This metric captures the portion of deferred revenue from research and development service contracts that is expected to be recognized as revenue within the next twelve months. It reflects the short-term service obligations the company must fulfill to satisfy its contractual requirements. This is a key indicator of near-term revenue realization from existing R&D partnerships.
Ask your AI about BridgeBio Pharma's research and development services — deferred revenue, current portion.
Connect your AI assistant and compare it to peers, right in your chat.
